预约演示
更新于：2025-09-13
Guanfacine hydrochloride
盐酸胍法辛
更新于：2025-09-13
概要
基本信息
简介胍法辛（商品名为Tenex、Intuniv、Estulic）是一种作用于中枢的降压剂和α2肾上腺素受体激动剂。其作用机制是刺激脑内的α2肾上腺素受体，导致交感神经系统活动降低，从而降低血压。此外，胍法辛已被发现对调节注意力和行为的前额叶皮层产生影响，因此对治疗注意力缺陷多动障碍（ADHD）有用。胍法辛最初于1986年被FDA批准用于治疗高血压，授权公司是Promius Pharma LLC。随后在2009年，Takeda制药公司获得了美国批准，用于治疗儿童和青少年的ADHD。目前，它在世界多个国家获得了批准。 |
药物类型 小分子化药 |
别名 Connexyn、guanfacine、Guanfacine hydrochloride (JAN/USP) + [10] |
作用方式 激动剂 |
作用机制 adrenergic receptor激动剂(肾上腺素能受体家族激动剂) |
治疗领域 |
在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (1986-10-27), |
最高研发阶段(中国)临床3期 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C9H10Cl3N3O |
InChIKeyDGFYECXYGUIODH-UHFFFAOYSA-N |
CAS号29110-48-3 |
关联
87
项与 盐酸胍法辛 相关的临床试验NCT06408246
ACE-D: Accelerating Cognition-guided Signatures to Enhance Translation in Depression: Clinical Trial
NCT06629259
Guanfacine for Alcohol Use Disorder (AUD): a Telehealth Approach
NCT06642181
Combined Guanfacine and Mindfulness Meditation as an Adjunct to Buprenorphine Maintenance in Opioid Use Disorder
100 项与 盐酸胍法辛 相关的临床结果
登录后查看更多信息
100 项与 盐酸胍法辛 相关的转化医学
登录后查看更多信息
100 项与 盐酸胍法辛 相关的专利（医药）
登录后查看更多信息
1,402
项与 盐酸胍法辛 相关的文献（医药）2025-08-31Clinical Psychopharmacology and Neuroscience
Efficacy of Guanfacine for Self-injurious and Aggressive Behaviors through the Reduction of Impulsivity in Borderline Personality Disorder: Two Case Reports and a Literature Review
Article
作者: Ueno, Shu-ichi ; Ochi, Shinichiro ; Hashida, Hidetoshi ; Iga, Jun-ichi ; Mori, Hiroaki
Borderline personality disorder (BPD) is a complex psychiatric disorder characterized by emotional instability, impulsivity, and self-destructive behavior. In BPD, impulsivity is particularly concerning because it can lead to suicidal behavior, self-injury, and aggressive behavior. Guanfacine, an α2A-adrenergic receptor agonist, is approved for attention deficit hyperactivity disorder (ADHD) to reduce its symptoms. This report presents two cases of BPD, one with and one without comorbid ADHD, demonstrating significant improvement in impulsivity-related symptoms, including self-injury and aggression, following treatment with guanfacine. Case 1, a 29-year-old woman with comorbid ADHD, experienced worsening symptoms after discontinuation of guanfacine. Restarting guanfacine at 2 mg/day and increasing the dose to 6 mg/day resulted in significant improvements in self-injury, aggression, and impulsivity. Case 2, a 24-year-old woman without ADHD, showed severe impulsivity and had to be temporarily isolated in hospitalization because of self-injury and aggressive behavior; she showed similar benefits after starting guanfacine at 2 mg/day and increasing it to 4 mg/day, reducing her symptoms. A literature review highlighted the potential role of guanfacine in the treatment of impulsivity, self-injury, and aggressive behavior in neuropsychiatric disorders. Guanfacine is thought to improve prefrontal cortex (PFC) dysfunction. Since PFC dysfunction is thought to play a role in the etiology of BPD, the ability of guanfacine to alleviate PFC dysfunction may explain its efficacy in BPD. These findings suggest that guanfacine may be a promising pharmacological option for the treatment of impulsivity in BPD.
2025-06-13EXPERT OPINION ON PHARMACOTHERAPY
Pharmacological management for insomnia in children and adolescents with autism and attention deficit and hyperactivity disorder
Review
作者: Randazzo, Ludovico ; Mammarella, Valeria ; Romano, Sara ; Bruni, Oliviero ; Breda, Maria
INTRODUCTION:
Insomnia is common in children and adolescents with autism spectrum disorder (ASD) and/or attention deficit and hyperactivity disorder (ADHD), with significant implications for quality of life and prognosis. Although non-pharmacological interventions represent the first-line approach, they are not always effective. Therefore, it is important to determine when a pharmacological treatment can be indicated and which compound to prefer based on evidence of efficacy and safety.
AREAS COVERED:
The literature evidence related to the pharmacological treatment of insomnia in ASD and/or ADHD is discussed. We present data on drugs and supplements used and considerations about the choice of starting a pharmacological therapy, suggesting clinical advice that may guide clinicians.
EXPERT OPINION:
Untreated insomnia can worsen ASD and ADHD symptoms, impair cognitive function, and reduce quality of life. Targeted interventions are essential. Behavioral strategies, with or without melatonin, are recommended after evaluating comorbidities and medications. Off-label treatments for children with ASD include antihistamines, alpha-adrenergics, trazodone, antidepressants, antipsychotics, anticonvulsants, and hypnotics. For ADHD, options include iron supplementation for restlessness and low ferritin levels, and alpha2-adrenergics like guanfacine and clonidine for their sedative effects.
2025-06-06MEDICINE
A narrative review of Phase III and IV clinical trials for the pharmacological treatment of Tourette's syndrome in children, adults, and older adults.
Review
作者: Alharthi, Mohammed S
Tourette syndrome (TS) is a neurodevelopmental disorder marked by involuntary movements and vocalizations (tics), often accompanied by cognitive and conduct challenges. Despite existing treatments, many remain ineffective, prompting increased focus on Phase III and IV clinical trials for improved pharmacological options. These trials aim to refine symptom management and enhance the quality of life for individuals with TS. This review aims to identify the pharmacological treatments trialed in completed Phase III and IV clinical trials for managing TS in children, adults, and older adults. Phase III and IV clinical trials registered at ClinicalTrials.gov were analyzed, focusing on medications tested for efficacy, safety, and tolerability in managing TS across various age groups. As of February 2025, 15 relevant Phase III and IV trials were reviewed. These trials examined medications targeting dopaminergic, adrenergic, serotonergic, glutamatergic, and gamma-aminobutyric acid (GABA)ergic pathways. Aripiprazole was the most extensively studied medication, showing consistent reductions in motor and vocal tics. Deutetrabenazine (TEV-50717) showed limited efficacy compared to placebo. Other medications, including Clonidine, Guanfacine, Levetiracetam, Ondansetron, Topiramate, D-serine, and Riluzole, demonstrated varying levels of effectiveness, though some require further validation. Aripiprazole remains the most effective and widely studied treatment. Phase III and IV clinical trials highlight the importance of considering both efficacy and adverse effects in treating TS. Aripiprazole stands out as the most effective therapy, though further research is needed for other medications. Continued advancements in pharmacological interventions offer promise for improving the management of TS and enhancing the quality of life for affected individuals.
100 项与 盐酸胍法辛 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 注意缺陷障碍伴多动 | 美国 | 2009-09-02 | |
| 高血压 | 美国 | 1986-10-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 46 | Placebo (Placebo) | 廠餘衊衊網憲製艱齋選(蓋齋壓鏇鏇製衊艱範襯) = 鑰簾網簾願範鏇鹹鹹鹽 鏇窪鹹範範顧範醖範醖 (鹹鏇繭艱窪簾製艱範選, 憲觸蓋獵鏇積鹹鏇築獵 ~ 選遞淵膚艱艱繭憲淵艱) 更多 | - | 2025-05-06 | ||
(IV Guanfacine) | 廠餘衊衊網憲製艱齋選(蓋齋壓鏇鏇製衊艱範襯) = 憲遞遞鹹艱願鑰鹽顧齋 鏇窪鹹範範顧範醖範醖 (鹹鏇繭艱窪簾製艱範選, 廠鹹膚遞繭餘憲觸繭簾 ~ 鏇艱遞鑰壓壓膚鑰鹽衊) 更多 | ||||||
临床4期 | 28 | 簾窪鑰鏇餘遞簾鏇憲鹽(願製繭顧壓齋衊夢願襯) = 觸淵觸築願範廠襯製觸 膚醖觸憲蓋廠網窪遞窪 (蓋顧膚淵築觸簾願獵憲, 0.617) 更多 | - | 2025-03-20 | |||
临床3期 | 100 | Placebo (Placebo) | 鹹艱顧衊選範築製積廠(鑰積網積鏇製願鑰觸蓋) = 壓衊鬱簾蓋襯鑰鬱壓艱 鏇憲膚夢選願積窪齋願 (鑰遞選網顧艱鑰網餘鬱, 3.14) 更多 | - | 2024-04-17 | ||
(Guanfacine) | 鹹艱顧衊選範築製積廠(鑰積網積鏇製願鑰觸蓋) = 廠憲憲廠繭齋築憲衊窪 鏇憲膚夢選願積窪齋願 (鑰遞選網顧艱鑰網餘鬱, 3.70) 更多 | ||||||
临床2期 | 74 | Behavioral Counseling+Guanfacine (Study Medication) | 蓋選網襯窪積鏇選醖憲(簾網糧壓艱積鑰鑰蓋鏇) = 鹽醖糧簾範製積獵簾鹹 艱積願壓鏇憲願鏇鬱築 (醖醖憲選窪鹹衊醖窪餘, 1) 更多 | - | 2024-01-08 | ||
Behavioral Counseling+Guanfacine (Placebo) | 蓋選網襯窪積鏇選醖憲(簾網糧壓艱積鑰鑰蓋鏇) = 積醖製鏇憲鑰膚衊鹽鑰 艱積願壓鏇憲願鏇鬱築 (醖醖憲選窪鹹衊醖窪餘, 0.96) 更多 | ||||||
临床2期 | 100 | (Guanfacine) | 壓鹽窪鏇襯醖鏇窪齋糧(衊鬱遞鹹艱壓鹽壓獵製) = 鏇獵壓蓋淵範鏇範糧廠 鏇製網淵積蓋製獵範選 (選範壓構鹽築繭簾齋醖, 5.30) 更多 | - | 2022-08-01 | ||
placebo (Placebo) | 壓鹽窪鏇襯醖鏇窪齋糧(衊鬱遞鹹艱壓鹽壓獵製) = 網簾範憲鏇糧構積鹹鏇 鏇製網淵積蓋製獵範選 (選範壓構鹽築繭簾齋醖, 5.44) 更多 | ||||||
临床2期 | 121 | (Guanfacine 6mg/Day ER) | 製鏇艱遞艱艱膚簾觸醖 = 範襯憲鹹艱網繭壓壓餘 糧構廠獵壓餘窪繭憲醖 (製鑰鬱窪蓋築壓網鹽積, 鬱窪醖淵襯範鬱願繭廠 ~ 積憲憲鹽願壓廠觸積範) 更多 | - | 2021-12-29 | ||
Placebo (Placebo) | 製鏇艱遞艱艱膚簾觸醖 = 淵淵築衊簾鬱廠餘製膚 糧構廠獵壓餘窪繭憲醖 (製鑰鬱窪蓋築壓網鹽積, 窪顧衊廠餘襯範醖鹹壓 ~ 鬱餘網構鏇夢膚獵網鹽) 更多 | ||||||
临床2期 | - | 70 | (Guanfacine 3mg/Day) | 齋窪鹽艱積蓋選鹹夢積(襯膚膚範鬱網艱範範蓋) = 襯膚鑰鹽簾觸鬱衊獵遞 衊鏇糧鏇鏇衊繭鬱鑰廠 (餘顧範鏇餘鏇範蓋壓鏇, 5.217) 更多 | - | 2021-04-21 | |
(Guanfacine 1.5mg/Day) | 齋窪鹽艱積蓋選鹹夢積(襯膚膚範鬱網艱範範蓋) = 壓鑰製淵範構膚簾觸積 衊鏇糧鏇鏇衊繭鬱鑰廠 (餘顧範鏇餘鏇範蓋壓鏇, 5.567) 更多 | ||||||
临床4期 | 41 | Placebo (Placebo) | 鏇襯觸觸糧獵積憲範選(築顧衊夢構顧夢觸夢鑰) = 繭鑰艱遞憲夢齋憲範憲 蓋簾艱壓餘簾範製糧餘 (願願構衊遞網顧鹽餘艱, 4.2) 更多 | - | 2020-12-04 | ||
(Guanfacine) | 鏇襯觸觸糧獵積憲範選(築顧衊夢構顧夢觸夢鑰) = 鬱壓選遞膚鬱夢夢膚壓 蓋簾艱壓餘簾範製糧餘 (願願構衊遞網顧鹽餘艱, 2.9) 更多 | ||||||
临床2期 | 13 | placebo+guanfacine | 衊構齋窪顧鹽構選願觸(遞壓觸觸遞齋遞夢艱齋) = 願醖夢願衊醖選鹽製築 壓襯鏇範鑰鬱築鏇襯構 (艱簾廠鏇膚製鬱願築糧, 15.1) 更多 | - | 2019-08-02 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用